Form 4: J&J Director John Morikis Buys Shares
Insider Transaction Report
Johnson & Johnson Director John G. Morikis acquired 1,250 shares of common stock at $206.15 per share, increasing his direct beneficial ownership to 1,848.51 shares.
Summary
- John G. Morikis, a Director of Johnson & Johnson (JNJ), acquired 1,250 shares of common stock.
- The transaction occurred on November 26, 2025, at a price of $206.15 per share.
- Following this purchase, Morikis directly beneficially owns 1,848.51 shares of Johnson & Johnson common stock.
- The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged purchase plan.
Sentiment
Score: 7
Explanation: A director's purchase of company stock is generally viewed as a positive signal, indicating confidence in the company's valuation and future prospects. However, the transaction size is relatively small for a company of Johnson & Johnson's scale.
Positives
- A Director's purchase of company stock signals confidence in the company's future prospects and valuation.
Future Outlook
This filing does not contain any forward-looking statements or guidance regarding the company's future performance.
Industry Context
This insider transaction reflects an individual director's investment decision and does not directly relate to broader industry trends or competitive landscape announcements.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Transaction Plan Disclosure | The reported transaction was made pursuant to a Rule 10b5-1(c) plan, which is a pre-arranged trading plan designed to allow insiders to buy or sell company stock without being accused of insider trading. | 11/26/2025 | Indicates adherence to corporate governance best practices for insider trading, providing a legal affirmative defense against claims of trading on material non-public information. |
Stakeholder Impact
- Shareholders may interpret the director's purchase as a positive indicator of management's belief in the company's value, potentially boosting investor confidence.
Key Dates
| Date | Description |
|---|---|
| 11/26/2025 | Date of common stock acquisition by John G. Morikis. |
| 12/01/2025 | Date the Form 4 was signed by attorney-in-fact for John Morikis. |
Recommendation
holdWhile a director's purchase signals confidence, this single transaction of 1,250 shares is not substantial enough to significantly alter the fundamental investment thesis for a large-cap company like Johnson & Johnson, warranting a 'hold' recommendation based solely on this filing. The transaction value is minor relative to JNJ's market capitalization and daily trading volume.
Keywords
Johnson & Johnson, JNJ, Insider Trading, Form 4, Stock Purchase, Director, Equity Acquisition, John Morikis, 10b5-1 Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.